文献速递慢性肾脏病

血浆和肽素作为肾脏疾病预测指标

Plasma copeptin as a predictor of kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2019-01-01

在马尔默预防项目再调查(n=5158)和马尔默饮食与癌症心血管队列(n=5162)中,血浆和肽素(血管加压素标志物)水平升高与随访期间慢性肾脏病(CKD)及其他特定肾脏疾病风险独立相关,提示其可用于识别肾脏病高风险个体。

要点

  • 血浆和肽素水平升高独立预测CKD发生风险。
  • 和肽素亦与CKD以外特定肾脏疾病风险相关。
  • 和肽素或可用于筛查肾脏病高风险人群。

核心结论

  • 血浆和肽素水平升高独立预测CKD及其他特定肾脏疾病的发生,提示其可用于识别肾脏病高风险个体。

研究设计与样本

  • 研究基于马尔默预防项目再调查(MPP,n=5158)和马尔默饮食与癌症心血管队列(MDC-CC,n=5162)两个队列,随访时间分别为8.7年和19.6年。

主要发现

  • 多变量调整后,在基线无肾脏病者中,和肽素每增加1个标准差(ln转换)与CKD风险增加独立相关(MPP:HR 1.46,95%CI 1.18-1.80,P<0.001;MDC-CC:HR 1.25,95%CI 1.02-1.54,P=0.03)。
  • MPP中,和肽素升高预测CKD以外特定肾脏疾病诊断(HR 1.31,95%CI 1.08-1.59,P=0.006);MDC-CC中风险增加10%但无统计学意义(P=0.25)。
  • 两项数据荟萃分析显示,和肽素升高与CKD以外特定肾脏疾病诊断显著相关(HR 1.18,95%CI 1.05-1.34,P=0.008)。

临床怎么用

  • 临床可考虑检测血浆和肽素以辅助识别肾脏病高风险个体,但需结合其他临床指标综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plasma copeptin, a marker of vasopressin, is associated with renal function decline in the general population. Our aim was to study the links between elevated copeptin and future risk of kidney disease. METHODS: Copeptin was measured in a sample of the Malmö Preventive Project (MPP) Reinvestigation (n = 5158) and in the Malmö Diet and Cancer Cardiovascular Cohort (MDC-CC) (n = 5162). According to national registers, 89 subjects in MPP and 180 in MDC-CC developed chronic kidney disease (CKD) during follow-up (8.7 and 19.6 years, respectively). RESULTS: After multivariate adjustment (gender, age, body mass index, smoking status, estimated glomerular filtration rate, prevalent diabetes, systolic blood pressure and prevalent antihypertensive treatment), copeptin (beta-coefficient per 1 standard deviation increment of ln copeptin) was independently associated with increased risk of CKD during follow-up in both cohorts (MPP: (HR) 1.46, 95% confidence interval (CI) 1.18-1.80, P < 0.001; MDC-CC: HR 1.25, 95% CI 1.02-1.54, P = 0.03) among subjects free from prevalent kidney disease at baseline. Furthermore, in MPP, elevated copeptin predicted a specified diagnosis of kidney disease other than CKD (HR 1.31, 95% CI 1.08-1.59, P = 0.006) after multivariate adjustment. In a corresponding analysis in MDC-CC, copeptin was associated with a 10% increased risk, which, however, was non-significant (P = 0.25). A meta-analysis of the MPP and MDC-CC data showed significant association between elevated copeptin and a specified diagnosis of kidney disease other than CKD (HR 1.18, 95% CI 1.05-1.34, P = 0.008). CONCLUSION: An increased level of copeptin independently predicts development of both CKD and other specified kidney diseases, suggesting that copeptin can be used to identify individuals at risk for kidney disease development.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Enhörning S, Christensson A, Melander O, et al. Plasma copeptin as a predictor of kidney disease. Nephrol Dial Transplant. 2019. PMID: 29471407. doi:10.1093/ndt/gfy017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。